Small cell undifferentiated (SCUD) hepatoblastomas: All malignant rhabdoid tumors?
暂无分享,去创建一个
[1] E. Gomulia,et al. Is INI1-retained small cell undifferentiated histology in hepatoblastoma unfavorable? , 2015, Human pathology.
[2] R. Siebert,et al. SMARCA4-mutated atypical teratoid/rhabdoid tumors are associated with inherited germline alterations and poor prognosis , 2014, Acta Neuropathologica.
[3] Yukichi Tanaka,et al. Towards an international pediatric liver tumor consensus classification: proceedings of the Los Angeles COG liver tumors symposium , 2014, Modern Pathology.
[4] R. Siebert,et al. High‐resolution genomic analysis suggests the absence of recurrent genomic alterations other than SMARCB1 aberrations in atypical teratoid/rhabdoid tumors , 2013, Genes, chromosomes & cancer.
[5] J. Feusner,et al. Rhabdoid tumors of the liver: Rare, aggressive, and poorly responsive to standard cytotoxic chemotherapy , 2011, Pediatric Blood & Cancer.
[6] A. Zimmermann,et al. INI1 (BAF 47) Immunohistochemistry is an Essential Diagnostic Tool for Children With Hepatic Tumors and Low Alpha Fetoprotein , 2010, Journal of pediatric hematology/oncology.
[7] R. Siebert,et al. Germline nonsense mutation and somatic inactivation of SMARCA4/BRG1 in a family with rhabdoid tumor predisposition syndrome. , 2010, American journal of human genetics.
[8] R. Siebert,et al. Clinical and molecular features in patients with atypical teratoid rhabdoid tumor or malignant rhabdoid tumor , 2010, Genes, chromosomes & cancer.
[9] C. Rodríguez-Galindo,et al. Age, stage, and radiotherapy, but not primary tumor site, affects the outcome of patients with malignant rhabdoid tumors , 2010, Pediatric blood & cancer.
[10] N. Sebire,et al. Clinical and pathological features of paediatric malignant rhabdoid tumours , 2010, Pediatric blood & cancer.
[11] A. Pappo,et al. Amifostine does not prevent platinum‐induced hearing loss associated with the treatment of children with hepatoblastoma , 2009, Cancer.
[12] G. Tomlinson,et al. Small cell undifferentiated variant of hepatoblastoma: Adverse clinical and molecular features similar to rhabdoid tumors , 2009, Pediatric blood & cancer.
[13] J. Biegel,et al. Malignant Rhabdoid Tumor Mimicking Hepatoblastoma: A Case Report and Literature Review , 2007, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[14] R. Siebert,et al. Non‐linkage of familial rhabdoid tumors to SMARCB1 implies a second locus for the rhabdoid tumor predisposition syndrome , 2006, Pediatric blood & cancer.
[15] W. London,et al. Intensified platinum therapy is an ineffective strategy for improving outcome in pediatric patients with advanced hepatoblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] G. Tiao,et al. The current management of hepatoblastoma: a combination of chemotherapy, conventional resection, and liver transplantation. , 2005, The Journal of pediatrics.
[17] J. Biegel,et al. Immunohistochemical Analysis of hSNF5/INI1 Distinguishes Renal and Extra-renal Malignant Rhabdoid Tumors From Other Pediatric Soft Tissue Tumors , 2004, The American journal of surgical pathology.
[18] J. Biegel,et al. Immunohistochemical Analysis of hSNF5/INI1 in Pediatric CNS Neoplasms , 2004, The American journal of surgical pathology.
[19] G. Perilongo,et al. Risk-adapted treatment for childhood hepatoblastoma. final report of the second study of the International Society of Paediatric Oncology--SIOPEL 2. , 2004, European journal of cancer.
[20] D. V. von Schweinitz,et al. [Differentiated treatment protocols for high- and standard-risk hepatoblastoma--an interim report of the German Liver Tumor Study HB99]. , 2003, Klinische Padiatrie.
[21] F. Gilles,et al. Aberrations of the hSNF5/INI1 gene are restricted to malignant rhabdoid tumors or atypical teratoid/rhabdoid tumors in pediatric solid tumors , 2002, Genes, chromosomes & cancer.
[22] J. Feusner,et al. Small cell undifferentiated histology in hepatoblastoma may be unfavorable , 2001 .
[23] M. Yaniv,et al. The murine SNF5/INI1 chromatin remodeling factor is essential for embryonic development and tumor suppression , 2000, EMBO reports.
[24] J. Quinn,et al. Randomized comparison of cisplatin/vincristine/fluorouracil and cisplatin/continuous infusion doxorubicin for treatment of pediatric hepatoblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] Olivier Delattre,et al. Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer , 1998, Nature.
[26] J. Biegel,et al. Narrowing the critical region for a rhabdoid tumor locus in 22q11 , 1996, Genes, chromosomes & cancer.
[27] D. V. von Schweinitz,et al. Complete resection before development of drug resistance is essential for survival from advanced hepatoblastoma--a report from the German Cooperative Pediatric Liver Tumor Study HB-89. , 1995, Journal of pediatric surgery.
[28] G. Crabtree,et al. Binding and stimulation of HIV-1 integrase by a human homolog of yeast transcription factor SNF5. , 1994, Science.
[29] C. Anthony. Tumors of the liver. , 1983, Seminars in roentgenology.
[30] T. Hishiki,et al. The Children's Hepatic tumors International Collaboration (CHIC): Novel global rare tumor database yields new prognostic factors in hepatoblastoma and becomes a research model. , 2016, European journal of cancer.
[31] S. Kondo,et al. Outcome of hepatoblastomas treated using the Japanese Study Group for Pediatric Liver Tumor (JPLT) protocol-2: report from the JPLT , 2010, Pediatric Surgery International.
[32] G. Perilongoa,et al. Risk-adapted treatment for childhood hepatoblastoma: final report of the second study of the International Society of Paediatric Oncology—SIOPEL 2§ , 2004 .
[33] J. Feusner,et al. Small cell undifferentiated histology in hepatoblastoma may be unfavorable. , 2001, Cancer.